Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as foundational therapies across the cardio-kidney-metabolic (CKM) syndrome. Initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM), these medications demonstrated substantial cardiovascular and renal benefits in large cardiovascular outcomes trials, fundamentally changing the management of heart failure (HF), chronic kidney disease (CKD), and T2DM. Early landmark trials, including EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS CV, established reductions in hospitalization for heart failure (HHF) and favorable renal outcomes in patients with T2DM, with more selective effects on atherosclerotic cardiovascular disease outcomes. Subsequent dedicated HF trials demonstrated that SGLT2 inhibitors provide clinically meaningful benefit across the left ventricular ejection fraction spectrum. In patients with heart failure with reduced ejection fraction (HFrEF), DAPA-HF and EMPEROR-Reduced showed significant reductions in worsening HF and cardiovascular death regardless of diabetes status. Similar benefits were later demonstrated in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) in EMPEROR-Preserved and DELIVER, establishing SGLT2 inhibitors as among the first therapy classes to consistently reduce HF events across the HF spectrum. Dedicated CKD trials, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY, further showed substantial slowing of kidney disease…
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.